Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan's Teijin To Apply For U.S.-Approved Gout Drug In Japan, Europe

This article was originally published in PharmAsia News

Executive Summary

Teijin Pharma of Japan says it is ready to seek approval in Japan and Europe to market a gout drug TMX-67 (febuxostat) that the maker expects will become a blockbuster. Teijin has had trouble getting the drug approved in Japan, where regulatory authorities required additional clinical trials, so Teijin plans to reapply this year, in time to release it locally in 2011. Takeda Pharmaceutical markets Teijin's drug in the United States as Uloric. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts